CANBRIDGE-B (01228.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec8

BiochemChina's CAN 103 Included in Commercial Insurance Catalog and Officially Enters Clinical Use

10:17

Sep28

BioMedicines Biologics Concludes Share Subscription Underwriting Settlement for HK$22,591,400

10:19

Sep15

Concord Pharmaceutical Issues 9,996,200 Shares to 3 Subscribers

14:51

Sep11

Concord Pharmaceutical's Shareholders Deposit Shares into 浦银国际证券

00:39

Sep8

Canbridge Pharmaceuticals Products Pass Initial Review and Reach Agreement With Byoncare

07:32

Aug31

CANBRIDGE-B released FY2025 Q1 earnings on August 31 (BJT), actual revenue HKD 11.91 M, actual EPS HKD 0.0749

15:00

Schedules & Filings

Schedules

Filings

Aug31

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 12.18 M, Net Income 32.42 M, EPS 0.0763

Aug29

Earning Release(CST)

FY2025 Semi-Annual Earning Release

Mar31

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 21.44 M, Net Income -103.91 M, EPS -0.2445

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change